文献速递血管炎

利妥昔单抗用于ANCA相关性血管炎复发后的缓解诱导治疗

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis.
PubMed 文献 · Ann Rheum Dis · 2020-06-24

基于RITAZAREM试验诱导期入组的前瞻性观察队列,188例复发的肉芽肿性多血管炎或显微镜下多血管炎患者接受利妥昔单抗(4×375 mg/m2)联合糖皮质激素诱导缓解。90%(171/188)患者在4个月内达到缓解,仅6例(3.2%)未实现疾病控制;诱导期4例死亡,27例发生41次严重不良事件(含13次严重感染)。

要点

  • 复发AAV患者接受利妥昔单抗联合糖皮质激素诱导,4个月缓解率达90%。
  • 仅3.2%患者4个月未达疾病控制,诱导期死亡率低但严重感染需关注。
  • 该方案在既往用过环磷酰胺或利妥昔单抗的复发人群中仍显示高效。

核心结论

  • 在复发性AAV患者中,利妥昔单抗联合糖皮质激素再诱导缓解具有高效性,安全性特征与既往研究相似。

研究设计与样本

  • 前瞻性观察队列,纳入RITAZAREM试验诱导期入组的188例复发性肉芽肿性多血管炎或显微镜下多血管炎患者。
  • 所有患者接受利妥昔单抗4×375 mg/m2,并根据医师选择采用较高或较低剂量糖皮质激素方案(从1 mg/kg/天或0.5 mg/kg/天减至4个月时10 mg/天)。

主要发现

  • 188例中95例(51%)为男性,中位年龄59岁(范围19-89),既往病程5.0年(范围0.4-34.5)。
  • 149例(79%)既往接受过环磷酰胺,67例(36%)既往接受过利妥昔单抗。
  • 119例(63%)复发时至少有一项主要疾病活动指标,54例(29%)接受较高剂量糖皮质激素方案。
  • 171例(90%)在4个月内达到缓解,仅6例(占研究人群3.2%)在4个月时未达到疾病控制。
  • 诱导期4例死亡(肺炎2例、脑血管意外1例、活动性血管炎1例),27例患者发生41次严重不良事件,包括13次严重感染。

关键数值与推荐

  • 缓解诱导方案:利妥昔单抗4×375 mg/m2联合糖皮质激素,糖皮质激素从1 mg/kg/天或0.5 mg/kg/天减至4个月时10 mg/天。
  • 主要疗效数值:4个月缓解率90%(171/188),未达疾病控制率3.2%(6/188)。

临床怎么用

  • 对于复发的肉芽肿性多血管炎或显微镜下多血管炎患者,可考虑利妥昔单抗联合糖皮质激素进行再诱导缓解。
  • 治疗期间需监测感染等严重不良事件,尤其是既往接受过免疫抑制治疗的患者。

局限性

  • 本研究为前瞻性观察队列,非随机对照试验,糖皮质激素剂量由医师选择。
  • 纳入患者来自RITAZAREM试验诱导期,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Evaluation of rituximab and glucocorticoids as therapy to induce remission after relapse in ANCA-associated vasculitis (AAV) in a prospective observational cohort of patients enrolled into the induction phase of the RITAZAREM trial. METHODS: Patients relapsing with granulomatosis with polyangiitis or microscopic polyangiitis were prospectively enrolled and received remission-induction therapy with rituximab (4×375 mg/m2) and a higher or lower dose glucocorticoid regimen, depending on physician choice: reducing from either 1 mg/kg/day or 0.5 mg/kg/day to 10 mg/day by 4 months. Patients in this cohort achieving remission were subsequently randomised to receive one of two regimens to prevent relapse. RESULTS: 188 patients were studied: 95/188 (51%) men, median age 59 years (range 19-89), prior disease duration 5.0 years (range 0.4-34.5). 149/188 (79%) had previously received cyclophosphamide and 67/188 (36%) rituximab. 119/188 (63%) of relapses had at least one major disease activity item, and 54/188 (29%) received the higher dose glucocorticoid regimen. 171/188 (90%) patients achieved remission by 4 months. Only six patients (3.2% of the study population) did not achieve disease control at month 4. Four patients died in the induction phase due to pneumonia (2), cerebrovascular accident (1), and active vasculitis (1). 41 severe adverse events occurred in 27 patients, including 13 severe infections. CONCLUSIONS: This large prospective cohort of patients with relapsing AAV treated with rituximab in conjunction with glucocorticoids demonstrated a high level of efficacy for the reinduction of remission in patients with AAV who have relapsed, with a similar safety profile to previous studies.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Smith RM, Jones RB, Specks U, et al. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis. 2020. PMID: 32581088. doi:10.1136/annrheumdis-2019-216863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。